Jpmorgan Chase & CO Celcuity Inc. Transaction History
Jpmorgan Chase & CO
- $1.23 Trillion
- Q4 2024
A detailed history of Jpmorgan Chase & CO transactions in Celcuity Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 14,683 shares of CELC stock, worth $189,851. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,683
Previous 12,007
22.29%
Holding current value
$189,851
Previous $179,000
7.26%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding CELC
# of Institutions
104Shares Held
30MCall Options Held
17.5KPut Options Held
100-
Bvf Inc San Francisco, CA3.47MShares$44.8 Million1.7% of portfolio
-
Baker Bros. Advisors LP New York, NY2.68MShares$34.6 Million0.39% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT2.57MShares$33.2 Million2.34% of portfolio
-
Perceptive Advisors LLC New York, NY2.36MShares$30.5 Million1.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.65MShares$21.4 Million0.0% of portfolio
About Celcuity Inc.
- Ticker CELC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 14,941,300
- Market Cap $193M
- Description
- Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therap...